Proceeding contribution from Paul Flynn (Labour) in the House of Commons on Thursday, 8 December 2005. It occurred during Estimates day on Department of Health.
Department of Health
Does the hon. Gentleman believe that, given the problems with Vioxx, which is just one of the COX-2 inhibitors, there is reason to look carefully at other such inhibitors? Some 1 million prescriptions were issued for Vioxx, but 3 million prescriptions have been issued for other COX-2 inhibitors that are still being prescribed.
Secondary information
- Type
- Proceeding contribution
- Reference
- 440 c1051
- Session
- 2005-06
- Chamber / Committee
- House of Commons chamber
- Subjects
- Advertising Licensing Expenditure Drugs Government departments Industry Prescription drugs Department of Health Medicines and Healthcare products Regulatory Agency Research Regulation Safety National Institute for Health and Care Excellence Registration Clinical trials
- Link
- View this Proceeding contribution on www.publications.parliament.uk
Librarians' tools
- Timestamp
- 2025-11-24 15:50:32 +0000
- URI
- http://data.parliament.uk/pimsdata/hansard/CONTRIBUTION_285140
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/pimsdata/hansard/CONTRIBUTION_285140
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/pimsdata/hansard/CONTRIBUTION_285140